Please select the option that best describes you:
Topics:
Ophthalmology • Neuro-Ophthalmology • Endocrinology • Thyroid Disorders • Oculoplastic Surgery • Primary Care
How often and in what way do you monitor patients who are receiving teprotumumab (Tepezza) for thyroid eye disease?
Answer from: at Community Practice
A week or two after completion unless having an issue.
Sign In or Register to read more